Insmed Company
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung
Technology:
Immunotherapy
Industry:
PharmTech
Headquarters:
Bridgewater, New Jersey, United States
Founded Date:
1988
Employees Number:
51-100
Funding Status:
IPO
Estimated Revenue:
$50M to $100M
Register and Claim Ownership